Antibiotics in the Treatment of Biliary Infection
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Medical Review(S) Clinical Review
CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................ -
“Ceftriaxone– Sulbactam–EDTA” and Various Antibiotics Against Gram
ORIGINAL ARTICLE A Comparative In Vitro Sensitivity Study of “Ceftriaxone– Sulbactam–EDTA” and Various Antibiotics against Gram- negative Bacterial Isolates from Intensive Care Unit Sweta Singh1, Chinmoy Sahu2, Sangram Singh Patel3, Abhay Singh4, Nidhi Yaduvanshi5 ABSTRACT Introduction: A rapid increase in multidrug-resistant (MDR) strains is being seen across the globe especially in the Southeast Asian region, including India. Carbapenems and colistin form the mainstay of treatment against gram-negative pathogens, especially extended-spectrum beta-lactamase (ESBL)- and metallo-beta-lactamse (MBL)-producing isolates. However, due to increased resistance to carbapenems and toxicity of colistin, especially in intensive care units (ICUs), carbapenem-sparing antibiotics like ceftriaxone–sulbactam–EDTA (CSE) combination needs to be evaluated. Materials and methods: Bacterial isolates cultured from various clinical samples from all ICUs for a period of 9 months were evaluated. Bacterial identification was performed by matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) and antibiotic susceptibility testing were performed by disk diffusion and E test method. Antibiogram of various antibiotics was noted. Extended-spectrum beta-lactamase- and MBL-producing bacteria were identified by phenotypic methods. Antibiotic sensitivity results of CSE were compared with the comparator drugs like colistin, carbapenems, and tigecycline in Enterobacteriaceae, Acinetobacter spp., and Pseudomonas spp. along with ESBL and MBL producers. Results: A total of 2,760 samples of blood, cerebrospinal fluid (CSF), respiratory samples, tissue, and pus were collected from ICUs with maximum isolates from pus (37%) followed by respiratory samples (31%) and blood (27%). Escherichia coli and Klebsiella pneumoniae were the predominant gram-negative pathogens accounting for 56% of the isolates followed by Acinetobacter spp. -
Cefoperazone Sodium
Disclaimer While these labels are the most current Drug Control Authority (DCA) approved versions of content, these are not necessarily reflective of final printed labeling currently in distribution LPD Title : Cefoperazone Sodium LPD Date : 07 February 2017 Country : Malaysia Reference : CDS version 5.0 dated 07 January 2017 Reason : Addition of adverse drug reactions (ADRs) Haemorrhage and Coagulopathy to Section 4.8 Undesirable effects, and also, addition of serious hemorrhage and coagulopathy to the warning about vitamin K deficiency in Section 4.4 Special warnings and precautions for use Addition of ADRs Anaphylactic reaction and Anaphylactic shock to Section 4.8 Undesirable effects Addition of ADR Dermatitis exfoliative to Section 4.8 Undesirable Effects and a warning statement on severe cutaneous adverse reactions (SCARs) to Section 4.4, Special warnings and precautions for use 1. NAME OF THE MEDICINAL PRODUCT CEFOBID 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Cefoperazone sodium is a semisynthetic broad-spectrum cephalosporin antibiotic for parenteral use only. Cefoperazone contains 34 mg sodium (1.5 mEq) per gram. Cefoperazone is a white crystalline powder which is freely soluble in water. The pH of a 25% aqueous solution is 5.0 to 6.5 and the solution is colorless to straw-yellow, depending on the concentration. The empirical formula is C25H26N9NaO8S2. 3. PHARMACEUTICAL FORM Cefoperazone sodium is available in vials containing 1 and 2 grams. Not For Distribution PFIZER CONFIDENTIAL Not all product strengths or pack sizes -
Antibiotic Resistance and Molecular Typing of Pseudomonas Aeruginosa: Focus on Imipenem
BJID 2002; 6 (February) 1 Antibiotic Resistance and Molecular Typing of Pseudomonas aeruginosa: Focus on Imipenem Ana Lúcia Peixoto de Freitas and Afonso Luis Barth Federal University of Rio Grande do Sul, Pharmacy School, Clinical Hospital of Porto Alegre, Cardiology Institute, Porto Alegre, RS; Catholic University of Pelotas, Pharmacy School, Pelotas, RS, Brazil Susceptibility tests by disk diffusion and by E-test and molecular typing by macrorestriction analysis were performed to determine the relatedness of Pseudomonas aeruginosa isolates from three distinct hospitals. The resistance profile of 124 isolates to 8 antimicrobial agents was determined in three different hospitals, in Porto Alegre, Brazil. Frequencies of susceptibility ranged from 43.9% for carbenicillin to 87.7% for ceftazidime. Cross-resistance data of imipenem-resistant isolates indicated that most (70%) were also resistant to carbenicillin, although 30% remained susceptible to ceftazidime and cefepime. In general, susceptibility profiles were not able to determine relatedness among isolates of P. aeruginosa. On the other hand, molecular typing by macrorestriction analysis demonstrated high discriminatory power and identified 66 strains among 72 isolates of P. aeruginosa. Imipenem-susceptible isolates were all different. However, identical clones of imipenem-resistant isolates were found in two of the hospitals, despite variable response to other antibiotics. No clustering of infection among the different medical centers was observed. In conclusion, clones of P. aeruginosa did not spread among the different hospitals in our city even though related isolates of imipenem- resistant P. aeruginosa were found. Key Words: Pseudomonas aeruginosa, antibiotic resistance, imipenem. Despite improvements in antibiotic therapy, However, nosocomial isolates may easily develop Pseudomonas aeruginosa remains as one of the most resistance to carbapenens due to reduced uptake of prominent Gram-negative bacteria causing hospital- the drug, which leads to outbreaks of multiresistant/ associated infections. -
28912 Oxoid FDA Cartridge Tables:1
* Adapted in part from CLSI document M100-S23 (M02-A11) : “Disc diffusion supplemental tablesʼʼ Performance standards for antimicrobial susceptibility testing. The complete standard may be obtained from the Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19807. Test Cultures (zone diameters in mm) Antimicrobial Agent Disc Code Potency Resistant Intermediate Susceptible Amikacin AK 30 μg EnterobacteriaceaeK, P. aeruginosa, Acinetobacter spp., and Staphylococcus spp. ≤14 15-16 ≥17 Amoxycillin - Clavulanic Acid AMC 20/10 μg EnterobacteriaceaeE ≤13 14-17 ≥18 Staphylococcus spp.A,Q ≤19 — ≥20 Haemophilus spp.A,Y ≤19 — ≥20 AmpicillinC,n AMP 10 μg EnterobacteriaceaeE and Vibrio choleraef ≤13 14-16 ≥17 Staphylococcus spp.A,Q ≤28 — ≥29 Enterococcus spp.A,V,W,k,m ≤16 — ≥17 Haemophilus spp.Y ≤18 19-21 ≥22 Streptococcus spp. ß-Hemolytic GroupA,d — — ≥24 Ampicillin – Sulbactam SAM 10/10 μg EnterobacteriaceaeE, Acinetobacter spp., and Staphylococcus spp. ≤11 12-14 ≥15 Haemophilus spp.A,Y ≤19 — ≥20 Azithromycin AZM 15 μg Staphylococcus spp., Streptococcus spp Viridans Groupn, ß-Hemolytic Group, and S. pneumoniae) ≤13 14-17 ≥18 Neisseria meningitidisA,i — — ≥20 Haemophilus spp.A — — ≥12 Aztreonam ATM 30 μg EnterobacteriaceaeE ≤17 18-20 ≤21 P. aeruginosa ≤15 16-21 ≥22 Haemophilus spp.A — — ≥26 CAR 100 μg Carbenicillin Enterobacteriaceae ≤19 20-22 ≥23 Pseudomonas aeruginosaP ≤13 14-16 ≥17 CEC 30 μg Cefaclor Enterobacteriaceae and Staphylococcus spp. ≤14 15-17 ≥18 Haemophilus spp.Y ≤16 17-19 ≥20 MA 30 μg Cefamandole EnterobacteriaceaeD,E and Staphylococcus spp. ≤14 15-17 ≥18 CefazolinG KZ 30 μg Staphylococcus spp. -
The Activity of Mecillinam Vs Enterobacteriaceae Resistant to 3Rd Generation Cephalosporins in Bristol, UK
The activity of mecillinam vs Enterobacteriaceae resistant to 3rd generation cephalosporins in Bristol, UK Welsh Antimicrobial Study Group Grŵp Astudio Wrthfiotegau Cymru G Weston1, KE Bowker1, A Noel1, AP MacGowan1, M Wootton2, TR Walsh2, RA Howe2 (1) BCARE, North Bristol NHS Trust, Bristol BS10 5NB (2) Welsh Antimicrobial Study Group, NPHS Wales, University Hospital of Wales, CF14 4XW Introduction Results Results Results Figure 1: Population Distributions of Mecillinam MICs for E. Figure 2: Population Distributions of MICs for ESBL- Resistance in coliforms to 3rd generation 127 isolates were identified by screening of which 123 were confirmed as resistant to CTX or coli (n=72), NON-E. coli Enterobacteriaceae (n=47) and multi- producing E. coli (n=67) against mecillinam or mecillinam + cephalosporins (3GC) is an increasing problem resistant strains (n=39) clavulanate CAZ by BSAC criteria. The majority of 3GC- both in hospitals and the community. Oral options MR Non-E. coli E. coli Mecalone Mec+Clav resistant strains were E. coli 60.2%, followed by for the treatment of these organisms is often 35 50 Enterobacter spp. 16.2%, Klebsiella spp. 12.2%, limited due to resistance to multiple antimicrobial 45 and others (Citrobacter spp., Morganella spp., 30 classes. Mecillinam, an amidinopenicillin that is 40 Pantoea spp., Serratia spp.) 11.4%. 25 available in Europe as the oral pro-drug 35 All isolates were susceptible to meropenem with s 20 30 e s pivmecillinam, is stable to many beta-lactamases. t e a t l a mecillinam the next most active agent with more l o 25 o s We aimed to establish the activity of mecillinam i s i 15 % than 95% of isolates susceptible (table). -
Acute Onset Flank Pain-Suspicion of Stone Disease (Urolithiasis)
Date of origin: 1995 Last review date: 2015 American College of Radiology ® ACR Appropriateness Criteria Clinical Condition: Acute Onset Flank Pain—Suspicion of Stone Disease (Urolithiasis) Variant 1: Suspicion of stone disease. Radiologic Procedure Rating Comments RRL* CT abdomen and pelvis without IV 8 Reduced-dose techniques are preferred. contrast ☢☢☢ This procedure is indicated if CT without contrast does not explain pain or reveals CT abdomen and pelvis without and with 6 an abnormality that should be further IV contrast ☢☢☢☢ assessed with contrast (eg, stone versus phleboliths). US color Doppler kidneys and bladder 6 O retroperitoneal Radiography intravenous urography 4 ☢☢☢ MRI abdomen and pelvis without IV 4 MR urography. O contrast MRI abdomen and pelvis without and with 4 MR urography. O IV contrast This procedure can be performed with US X-ray abdomen and pelvis (KUB) 3 as an alternative to NCCT. ☢☢ CT abdomen and pelvis with IV contrast 2 ☢☢☢ *Relative Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate Radiation Level Variant 2: Recurrent symptoms of stone disease. Radiologic Procedure Rating Comments RRL* CT abdomen and pelvis without IV 7 Reduced-dose techniques are preferred. contrast ☢☢☢ This procedure is indicated in an emergent setting for acute management to evaluate for hydronephrosis. For planning and US color Doppler kidneys and bladder 7 intervention, US is generally not adequate O retroperitoneal and CT is complementary as CT more accurately characterizes stone size and location. This procedure is indicated if CT without contrast does not explain pain or reveals CT abdomen and pelvis without and with 6 an abnormality that should be further IV contrast ☢☢☢☢ assessed with contrast (eg, stone versus phleboliths). -
Piperacillin-Tazobactam Allergies: an Exception to Usual Penicillin Allergy
Allergy Asthma Immunol Res. 2021 Mar;13(2):284-294 https://doi.org/10.4168/aair.2021.13.2.284 pISSN 2092-7355·eISSN 2092-7363 Original Article Piperacillin-Tazobactam Allergies: An Exception to Usual Penicillin Allergy Jane CY Wong ,1 Elaine YL Au ,2 Heather HF Yeung ,2 Chak-Sing Lau ,1 Philip Hei Li 1* 1Division of Rheumatology and Clinical Immunology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong 2Division of Clinical Immunology, Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Hong Kong Received: Apr 21, 2020 Revised: Jul 20, 2020 ABSTRACT Accepted: Jul 26, 2020 Purpose: The majority of penicillin allergy labels are false, and skin tests (ST) have high Correspondence to negative predictive value (NPV) of up to 90%. Piperacillin-tazobactam (PT) allergy has been Philip Hei Li, MBBS, FHKCP suspected to be an exception to this, but existing literature is scarce. We investigate the Division of Rheumatology & Clinical Immunology, Department of Medicine, The epidemiology, clinical characteristics, testing outcomes and predictive value of ST in patients University of Hong Kong, Queen Mary Hospital, referred for suspected PT allergies. 102 Pokfulam Road, Hong Kong. Methods: The records of all patients referred for suspected PT allergy testing and Tel: +852-2255-3348 prescription rates of PT in all Hong Kong public hospitals (2015–2019) were analyzed. Fax: +852-2816-2863 Results: There was an increase in both PT prescriptions and number of newly reported E-mail: [email protected] PT allergies between 2015 and 2019. The majority (91.1%) of patients with suspected PT Copyright © 2021 The Korean Academy of allergy had at least 1 underlying medical co-morbidity or immunosuppressant use leading to Asthma, Allergy and Clinical Immunology • increased risk of infections. -
Mecillinam (FL 1060), a 6,3-Amidinopenicillanic Acid Derivative: Bactericidal Action and Synergy in Vitro L
ANTUCROBIAL AGENTS AND CHEzOTHrAPY, Sept. 1975, p. 271-276 Vol. 8, No. 3 Copyright 0 1975 American Society for Microbiology Printed in U.S.A. Mecillinam (FL 1060), a 6,3-Amidinopenicillanic Acid Derivative: Bactericidal Action and Synergy In Vitro L. TYBRING* AND N. H. MELCHIOR Bacteriological Research Department, Leo Pharmaceutical Products, DK-2750 Ballerup, Denmark Received for publication 26 December 1974 A newly described 6d-amidinopenicillanic acid derivative, mecillinam (for- merly called FL 1060), showed a high in vitro activity against Enterobacteriac- eae. The effect on Escherichia coli was bactericidal and was due to lysis of the cells. The longer the culture grew under the influence of mecillinam or the lower the inoculum, the greater the bactericidal effect. The morphology of the cells changed towards large spheric forms (2 to 5 ,m) under the influence of mecillinam. Consequently a great discrepancy between the optical density and the viable count was seen. The morphologically abnormal cells could be protected against lysis in vitro by addition of ionized compounds such as sodium chloride. Abnormal cells were more sensitive to ampicillin than normal cells. As expected synergy could be demonstrated between mecillinam and ampicillin. This was marked under experimental conditions where the abnormal cells were protected against lysis. In a previous paper from this laboratory a new the liquid media was measured by the cryostatic group of penicillanic acid derivatives, 6,- method using a Knauer type M osmometer, and the amidinopenicillanic acids, with unusual in specific conductivity was measured as millisiemens at vitro antibacterial properties was described (4). 36 C using a conductivity meter, Radiometer type One member of CDM 2c. -
Orally Active Esters of Cephalosporin Antibiotics. Ii
VOL. XXXII NO. 11 THE JOURNAL OF ANTIBIOTICS 1155 ORALLY ACTIVE ESTERS OF CEPHALOSPORIN ANTIBIOTICS. II SYNTHESIS AND BIOLOGICAL PROPERTIES OF THE ACETOXYMETHYL ESTER OF CEFAMANDOLE WALTER E. WRIGHT, WILLIAM J. WHEELER, VERLE D. LINE, JUDITH ANN FROGGE' and DON R. FINLEY Lilly Research Laboratories, Eli Lilly and Company Indianapolis, Indiana 46206, U.S.A. (Received for publication August 29, 1979) The synthesis of the acetoxymethyl (AOM) ester of cefamandole (CM) is described. The sparingly soluble ester is shown to be well absorbed orally by mice, but only when administered in solution in a partially non-aqueous vehicle, 50°o propylene glycol. Neither the ester in aqueous suspension nor the sodium salt of CM in solution is well absorbed orally. The rate of oral absorption of the ester from solution is very rapid as shown by the early peak time and shape of the plasma level curve. Oral bioavailability from solution is at least 60% and is ap- parently limited only by hydrolysis or precipitation of a variable portion of the ester dose in the intestinal lumen prior to absorption. Esterification of the carboxyl group of penicillins and cephalosporins can result in significant improvement in the oral absorption of the parent drug. Pivampicillin1), bacampicillin2) and talampicil- lin3J are examples of such successful penicillin derivatives, and the acetoxymethyl ester of cephaloglycin4 and other cephalosporin derivatives') illustrate the applicability of this pro-drug principle to cephalo- sporins. Although the intact esters are biologically inactive, they can be hydrolyzed to the active parent drug either during passage through the intestinal wall or after absorption has occurred6). -
Guidelines on Urinary and Male Genital Tract Infections
European Association of Urology GUIDELINES ON URINARY AND MALE GENITAL TRACT INFECTIONS K.G. Naber, B. Bergman, M.C. Bishop, T.E. Bjerklund Johansen, H. Botto, B. Lobel, F. Jimenez Cruz, F.P. Selvaggi TABLE OF CONTENTS PAGE 1. INTRODUCTION 5 1.1 Classification 5 1.2 References 6 2. UNCOMPLICATED UTIS IN ADULTS 7 2.1 Summary 7 2.2 Background 8 2.3 Definition 8 2.4 Aetiological spectrum 9 2.5 Acute uncomplicated cystitis in pre-menopausal, non-pregnant women 9 2.5.1 Diagnosis 9 2.5.2 Treatment 10 2.5.3 Post-treatment follow-up 11 2.6 Acute uncomplicated pyelonephritis in pre-menopausal, non-pregnant women 11 2.6.1 Diagnosis 11 2.6.2 Treatment 12 2.6.3 Post-treatment follow-up 12 2.7 Recurrent (uncomplicated) UTIs in women 13 2.7.1 Background 13 2.7.2 Prophylactic antimicrobial regimens 13 2.7.3 Alternative prophylactic methods 14 2.8 UTIs in pregnancy 14 2.8.1 Epidemiology 14 2.8.2 Asymptomatic bacteriuria 15 2.8.3 Acute cystitis during pregnancy 15 2.8.4 Acute pyelonephritis during pregnancy 15 2.9 UTIs in post-menopausal women 15 2.10 Acute uncomplicated UTIs in young men 16 2.10.1 Pathogenesis and risk factors 16 2.10.2 Diagnosis 16 2.10.3 Treatment 16 2.11 References 16 3. UTIs IN CHILDREN 20 3.1 Summary 20 3.2 Background 20 3.3 Aetiology 20 3.4 Pathogenesis 20 3.5 Signs and symptoms 21 3.5.1 New-borns 21 3.5.2 Children < 6 months of age 21 3.5.3 Pre-school children (2-6 years of age) 21 3.5.4 School-children and adolescents 21 3.5.5 Severity of a UTI 21 3.5.6 Severe UTIs 21 3.5.7 Simple UTIs 21 3.5.8 Epididymo orchitis 22 3.6 Diagnosis 22 3.6.1 Physical examination 22 3.6.2 Laboratory tests 22 3.6.3 Imaging of the urinary tract 23 3.7 Schedule of investigation 24 3.8 Treatment 24 3.8.1 Severe UTIs 25 3.8.2 Simple UTIs 25 3.9 References 26 4. -
Antibacterial Drug Usage Analysis
Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Drug Use Review Date: April 5, 2012 To: Edward Cox, M.D. Director Office of Antimicrobial Products Through: Gerald Dal Pan, M.D., MHS Director Office of Surveillance and Epidemiology Laura Governale, Pharm.D., MBA Deputy Director for Drug Use Division of Epidemiology II Office of Surveillance and Epidemiology Hina Mehta, Pharm.D. Drug Use Data Analysis Team Leader Division of Epidemiology II Office of Surveillance and Epidemiology From: Tracy Pham, Pharm.D. Drug Use Data Analyst Division of Epidemiology II Office of Surveillance and Epidemiology Drug Name(s): Systemic Antibacterial Drug Products Application Type/Number: Multiple Applicant/sponsor: Multiple OSE RCM #: 2012-544 **This document contains proprietary drug use data obtained by FDA under contract. The drug use data/information in this document has been cleared for public release.** 1 EXECUTIVE SUMMARY The Division of Epidemiology II is providing an update of the drug utilization data in terms of number of kilograms or international units of selected systemic antibacterial drug products sold from manufacturers to various retail and non-retail channels of distribution for years 2010-2011 as a surrogate for nationwide antibacterial drug use in humans. Propriety drug use databases licensed by the FDA were used to conduct this analysis. Data findings are as follows: During years 2010 and 2011, the majority of kilograms of selected systemic antibacterial drug products sold were to outpatient retail pharmacy settings. Approximately 3.28 million kilograms of selected systemic antibacterial drug products were sold during year 2010, and around 3.29 million kilograms were sold during year 2011.